Lanthanide-based β-Tricalcium Phosphate Upconversion Nanoparticles as an Effective Theranostic Nonviral Vectors for Image-Guided Gene Therapy.


Journal

Nanotheranostics
ISSN: 2206-7418
Titre abrégé: Nanotheranostics
Pays: Australia
ID NLM: 101698994

Informations de publication

Date de publication:
2022
Historique:
received: 06 11 2021
accepted: 13 01 2022
entrez: 28 2 2022
pubmed: 1 3 2022
medline: 17 3 2022
Statut: epublish

Résumé

Lanthanide-based beta-tricalcium phosphate (β-TCP) upconversion nanoparticles are exploited as a non-viral vector for imaging guided-gene therapy by virtue of their unique optical properties and multi-modality imaging ability, high transfection efficiency, high biocompatibility, dispersibility, simplicity of synthesis and surface modification. Ytterbium and thulium-doped β-TCP nanoparticles (βTCPYbTm) are synthesized via co-precipitation method, coated with polyethylenimine (PEI) and functionalized with a nuclear-targeting peptide (TAT). Further,

Identifiants

pubmed: 35223382
doi: 10.7150/ntno.68789
pii: ntnov06p0306
pmc: PMC8864251
doi:

Substances chimiques

Calcium Phosphates 0
Lanthanoid Series Elements 0
beta-tricalcium phosphate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

306-321

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Drug Des Devel Ther. 2013 Jul 17;7:585-99
pubmed: 23898223
Pharm Res. 2002 Apr;19(4):377-81
pubmed: 12033367
Nat Protoc. 2012 Apr 19;7(5):935-45
pubmed: 22517260
J Biol Chem. 1997 Jun 20;272(25):16010-7
pubmed: 9188504
Nature. 1989 Jan 26;337(6205):387-8
pubmed: 2463491
J Mater Sci Mater Med. 2010 Aug;21(8):2393-401
pubmed: 20464457
J Pharm Sci. 2003 Feb;92(2):203-17
pubmed: 12532370
J Biotechnol. 2011 Apr 20;153(1-2):15-21
pubmed: 21356254
J Nucl Med. 2008 Jan;49(1):1-4
pubmed: 18077528
Virology. 1973 Apr;52(2):456-67
pubmed: 4705382
Exp Cell Res. 1990 Oct;190(2):170-4
pubmed: 2209719
ACS Appl Mater Interfaces. 2016 Mar;8(10):6391-9
pubmed: 26905516
Ther Deliv. 2012 May;3(5):623-32
pubmed: 22834406
Expert Rev Mol Diagn. 2005 Nov;5(6):893-905
pubmed: 16255631
Biochim Biophys Acta Biomembr. 2017 Dec;1859(12):2483-2494
pubmed: 28919344
Biomaterials. 2010 Mar;31(8):2064-71
pubmed: 20004969
Cytotechnology. 2017 Aug;69(4):655-665
pubmed: 28321779
Iran J Biotechnol. 2015 Mar;13(1):55-62
pubmed: 28959282
Biomaterials. 2005 Jun;26(17):3379-84
pubmed: 15621226
J Biotechnol. 2007 Feb 1;128(2):268-80
pubmed: 17118475
Peptides. 2014 Jul;57:78-94
pubmed: 24795041
SLAS Technol. 2018 Jun;23(3):281-293
pubmed: 29115174
J Mater Chem B. 2014 Jun 7;2(21):3282-3291
pubmed: 32261590
Chem Rev. 2008 Nov;108(11):4742-53
pubmed: 19006399
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Jul-Aug;2(4):349-66
pubmed: 20564463
Langmuir. 2010 May 18;26(10):7314-26
pubmed: 20112951
Chem Soc Rev. 2010 Jan;39(1):189-227
pubmed: 20023849
J Biomed Mater Res. 2001 Jun 5;55(3):409-14
pubmed: 11255195

Auteurs

Flavia Rodrigues Oliveira Silva (FRO)

Instituto de Pesquisas Energéticas e Nucleares, São Paulo, 05508-000, Brazil.
School of Chemistry, Faculty of Science, The University of New South Wales, Sydney NSW 2052, Australia.
School of Biotechnology and Biomolecular Sciences, Faculty of Science, The University of New South Wales, Sydney NSW 2052, Australia.

Nelson Batista Lima (NB)

Instituto de Pesquisas Energéticas e Nucleares, São Paulo, 05508-000, Brazil.

Maria Helena Bellini (MH)

Instituto de Pesquisas Energéticas e Nucleares, São Paulo, 05508-000, Brazil.

Luiz Felipe Silva Teixeira (LFS)

Instituto de Pesquisas Energéticas e Nucleares, São Paulo, 05508-000, Brazil.

Eric Yiwei Du (EY)

School of Chemistry, Faculty of Science, The University of New South Wales, Sydney NSW 2052, Australia.

Niloufar Jamshidi (N)

School of Chemistry, Faculty of Science, The University of New South Wales, Sydney NSW 2052, Australia.

Justin Gooding (J)

School of Chemistry, Faculty of Science, The University of New South Wales, Sydney NSW 2052, Australia.

Adam David Martin (AD)

Dementia Research Centre, Department of Biomedical Sciences, Macquarie University, Sydney, NSW 2019, Australia.

Alexander Macmillan (A)

Katharina Gaus Light Microscopy Facility, Mark Wainwright Analytical Centre, Lowy Cancer Research Centre, The University of New South Wales, Sydney, NSW 2052, Australia.

Christopher Peter Marquis (CP)

School of Biotechnology and Biomolecular Sciences, Faculty of Science, The University of New South Wales, Sydney NSW 2052, Australia.

Pall Thordarson (P)

School of Chemistry, Faculty of Science, The University of New South Wales, Sydney NSW 2052, Australia.
The UNSW RNA Institute, The University of New South Wales, Sydney NSW 2052, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH